Hiring in Japan Without Getting Stuck: A practical guide to Japan's employment model, its low labor mobility, and how the worker-dispatch (haken) system helps overseas companies keep fixed costs under control. Japan built its reputation on lifetime employment. Through the 20th century, people joined a company and stayed for a career — and that produced something special: deep loyalty, high engagement, and a real long-term commitment on both sides. That classic model is fading

Over the past two decades, the way medicines are made has quietly changed—from chemically synthesized small molecules to biologics manufactured inside cells and microbes. With that shift, the "horizontal division of labor" that separates drug discovery from manufacturing has become an industry norm, and the once-invisible role of contract development and manufacturing organizations (CDMOs) has stepped into the spotlight. The Japanese government, too, is placing this structura

FANUC and Yaskawa Electric are two of the world's four largest industrial robot makers. Sony holds more than half the global image-sensor market, and Nabtesco and Harmonic Drive dominate the precision reducers that drive robot joints. Lined up this way, Japan looks rock-solid in the age of physical AI. But the intuition is only half right — and that half-misalignment is exactly what decides whether foreign entrants succeed. Strong in the "body," weak in the "brain" and the "f

Demanding specifications are one of the wellsprings of the quality Japan is known for around the world. An uncompromising attention to detail has built products that customers trust. Yet that rigor carries an overlooked pitfall: the failure to separate what is necessary from what is merely sufficient. On the factory floor, the precision a part genuinely requires and the extra margin added "just in case" are too often run together as if they were the same thing. I learned this

What Foreign Biotech and Lab Equipment Makers Must Understand About Japan's B2B Procurement Culture When a foreign scientific instrument or industrial equipment maker enters the Japanese market, the obstacle they inevitably encounter isn't product quality or pricing. It's the structure of distribution and procurement customs. An end user — a researcher or procurement officer — may genuinely want to buy the product, yet the actual purchase order takes months. Multiple distribu

For many international biotech companies, Japan occupies an unusual position. It is too important to ignore, yet often perceived as too complex to prioritize. Consensus-driven decision-making, long relationship-building cycles, and cautious adoption processes are all commonly cited barriers to entry. Yet viewing Japan solely as a difficult market misses a much more important story. In bio-optics and bioimaging, Japan represents one of the world's most mature hardware ecosyste

Japan is the world's third-largest economy, home to some of the most sophisticated biomedical research institutions on the planet. Its universities produce world-class IP in gene therapy, regenerative medicine, next-generation antibodies, and optical instrumentation. By any measure, it should be one of the most competitive arenas for life science venture capital. It isn't. And for international VCs willing to pay attention, that gap represents one of the most compelling asymm

HSI Always Saw Too Much Hyperspectral imaging (HSI) captures food across hundreds of wavelength bands simultaneously, embedding chemical information into every pixel — moisture, protein, fat, microbial load, foreign objects. In theory, it's the perfect inspection tool: non-destructive, fast, and comprehensive. In practice, it spent decades being too hard to use. Two Fundamental Challenges 1. Data Volume Where a standard color image has three channels, a hyperspectral image ha